Plain-English translation of NCT05221359 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is an early-stage trial testing a new treatment called ExOlin® for adults whose type 1 diabetes is hard to manage despite using insulin pumps and continuous glucose monitors. The trial involves implanting a small device under the skin and then treating it with medication to see if it helps reduce dangerous blood sugar drops and large fluctuations. Researchers want to make sure the treatment is safe before testing it in larger groups of patients.
Some people with type 1 diabetes experience severe, unpredictable low blood sugar episodes and wild swings between high and low blood sugar that current treatments cannot adequately control. This trial exists to explore whether this new implanted device approach might offer better control and prevent these dangerous episodes.
You likely qualify if…
You likely don't qualify if…
You would go through a screening phase to confirm you are eligible, then have a minor surgical procedure to implant the small device under your skin. After implantation, you would receive the medication treatment and be closely monitored for safety. At the end of the trial, the device would be removed in another simple procedure. Throughout the study, you would have regular check-ins with the research team to monitor how you are doing.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France
Sponsor
Defymed
Enrollment target
~8 participants
Started
May 2022
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2022.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.